Sum­it­o­mo to make 200+ staff cuts in Mass­a­chu­setts amid con­sol­i­da­tion

Rough­ly a month af­ter an­nounc­ing plans to merge sev­er­al units un­der Sum­it­o­mo Phar­ma Amer­i­ca this Ju­ly, the drug­mak­er is mak­ing cuts in Mass­a­chu­setts.

Sum­it­o­mo Phar­ma Amer­i­ca Hold­ings and Sum­it­o­mo Phar­ma On­col­o­gy have an­nounced a com­bined 122 lay­offs to take ef­fect June 30, ac­cord­ing to Mass­a­chu­setts’ WARN sys­tem. An­oth­er Sum­it­o­mo unit, Sunovion Phar­ma­ceu­ti­cals, will make 101 cuts.

Sum­it­o­mo an­nounced in ear­ly April that it was com­bin­ing Sunovion, Sum­it­o­mo Phar­ma On­col­o­gy, Sum­it­o­mo Phar­ma Amer­i­ca Hold­ings, Sum­i­to­vant Bio­phar­ma, My­ovant Sci­ences, Urovant Sci­ences and En­zy­vant Ther­a­peu­tics to form Sum­it­o­mo Phar­ma Amer­i­ca. Sum­it­o­mo said at the time that the com­bined com­pa­ny would house a “di­verse port­fo­lio of com­mer­cial­ized prod­ucts and ro­bust pipeline of ear­ly- to late-stage as­sets” across the cen­tral ner­vous sys­tem, on­col­o­gy, urol­o­gy, women’s health, and cell and gene ther­a­pies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER